Latest Announcements

Investor Announcement, Clinical Trials

FDA End of Phase 2 Status Update

Prana Biotechnology has today announced the status of its End of Phase 2 discussions with the US Food and Drug Administration (FDA).


Huntington's Disease, Investor Announcement

The Lancet Neurology publishes Prana’s Huntington’s Disease Trial

The results of Prana’s Phase 2 trial in Huntington’s disease, Reach2HD, has been published in The Lancet Neurology, one of the world’s leading medical journals.


Movement disorders expert Professor Ira Shoulson joins Prana Biotechnology's Board of Directors

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"